Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-progestin versus progestin fertility-preserving therapy for young patients with early low-risk endometrial carcinoma or atypical endometrial hyperplasia
ChiCTR2200067099Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of leuprolide, letrozole, avatrombopag, medroxyprogesterone acetate and megestrol in endometrial cancer (EC) and Endometrial intraepithelial neoplasia (EIN) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete response rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
leuprolideletrozoleavatrombopagmedroxyprogesterone acetatemegestrol
03
Conditions
endometrial cancer (EC)Endometrial intraepithelial neoplasia (EIN)
Beyond the preview
Go deeper on ChiCTR2200067099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067099.